testosterone screening research: 7 Essential Findings About One Lab Result (2026)

One testosterone blood-test result is a measurement at one time—not, by itself, a reliable diagnosis of testosterone deficiency. In Brambilla and colleagues’ 2009 study of 66 men, testosterone measured at 4 p.m. averaged 20–25% lower than at 8 a.m. among men aged 30–40; the effect varied with age. The Endocrine Society’s 2018 guideline and July 2026 statement emphasize consistent symptoms, accurately measured concentrations and repeated early-morning results in clinical interpretation. The central conclusion of testosterone screening research is that timing, biological fluctuation, assay quality and clinical context all matter. [1,2,3]

Table of contents

1. What a single reading can tell us
2. Seven evidence-based findings
3. testosterone screening research: study comparison
4. Morning versus afternoon measurement
5. Biological and assay variability
6. Why repeat evidence changes interpretation
7. Lessons from TTrials and the 2026 military research letter
8. Research design and unanswered questions
9. Frequently asked questions
10. References

What a single reading can tell us

A laboratory result reports a measured concentration in a collected specimen using a particular analytical method. It may be informative, but it cannot automatically separate stable physiology from normal variation, temporary influences or measurement error. The number acquires meaning through the circumstances of collection, the assay, reference intervals and the broader question investigators are asking. That is why testosterone screening research starts with context.

This distinction is the foundation of testosterone screening research. Researchers are often interested in identifying people with persistently low concentrations, estimating the distribution of hormone values in populations, or defining eligibility for a carefully controlled trial. Those purposes are not identical, even if each involves reading testosterone from a laboratory report.

Testosterone is also not a perfectly static marker. Circulating concentrations fluctuate over the day and from one day to another. The extent of fluctuation differs among individuals and age groups. A value that crosses an arbitrary threshold once may not cross it when measured again, particularly if the original result lies near a boundary. This complicates testosterone screening research.

The Endocrine Society explicitly distinguishes biochemical results from a clinical diagnosis. Its 2018 guideline associates diagnosis with compatible symptoms and signs plus unequivocally and consistently low testosterone concentrations. This article describes that professional framework as research context; it does not translate it into personal testing or treatment instructions. [2]

Seven evidence-based findings

1. Collection time changes the measured value

Brambilla and colleagues examined temporal variation among 66 men aged 30–80 from a community survey. Samples were collected across three morning and three afternoon visits. Among men aged 30–40, their analysis found serum testosterone around 20–25% lower at 4 p.m. than at 8 a.m. Older men showed a smaller diurnal difference. [1]

This result explains why testosterone screening research treats clock time as a genuine study variable rather than a trivial administrative detail. Two specimens can represent the same person’s physiology at different points in a normal daily cycle. Comparing them as if they were gathered under identical conditions introduces avoidable uncertainty.

The study’s size and design also matter. These were repeated samples from a defined group, not a guarantee that every young man experiences the same percentage difference. Circadian patterns are biological averages with variation, and their measured effects depend on the sampling schedule and population. Responsible testosterone screening research retains those qualifications.

2. An afternoon threshold crossing can be transient

The Brambilla study reported that 17 men had at least one afternoon measurement below 300 ng/dL while all three of their morning measurements were above that value. The analysis included younger and older participants, illustrating that the classification difference was not confined to one age group. [1]

For testosterone screening research, this is a clear example of the difference between a threshold and an underlying state. One draw can fall below a cut point without consistently characterizing the participant across repeated observations. A screening flag and a diagnosis therefore refer to different levels of evidence.

The threshold in that experiment served as a way to illustrate classification instability. It should not be portrayed as a universally sufficient diagnostic rule, nor used to turn this educational article into an individual assessment tool. That boundary is essential for testosterone screening research.

3. Day-to-day fluctuation also matters

In a separate 2007 analysis, Brambilla, O’Donnell, Matsumoto and McKinlay examined intraindividual hormone variation among 132 men. The study used repeated blood sampling over several months and separated sources of variation. Biological variation generally contributed more to total variability than the laboratory assay component, with day-to-day effects particularly important. [4]

That work gives testosterone screening research a second reason to avoid overconfidence in one sample. Even when specimens are collected in a similar way, the biological system is not perfectly constant. A repeated result can reveal whether an initial observation reflects a stable tendency or normal variability.

The authors discussed ranges of expected differences across multiple measured hormones. Because those ranges were not specific to testosterone alone, it would be misleading to apply a pooled percentage as though it were an exact testosterone fluctuation for every individual. The stronger conclusion is qualitative: within-person variation is material and must be considered. This informs testosterone screening research.

4. Laboratory methods introduce another layer of uncertainty

An assay translates a chemical or immunological signal into a reported concentration. Different techniques can vary in specificity, calibration and accuracy, particularly near lower concentration ranges. Even a specimen collected at a standardized time may produce results that differ among laboratories or analytical platforms.

In its July 2026 statement, the Endocrine Society emphasized that nonstandardized methods can classify the same specimen differently and pointed to harmonized assays, including those certified through the U.S. Centers for Disease Control and Prevention’s Hormone Standardization Program. [3] Standardization supports reproducible testosterone screening research.

The message for testosterone screening research is that better biological sampling and better assay quality address different problems. Repeatedly using a biased test does not necessarily eliminate analytical bias. Similarly, a highly precise assay cannot remove natural hormonal variation. Reliable interpretation depends on both.

5. Total and free testosterone are not interchangeable concepts

Total testosterone includes hormone circulating in several binding states. Some is strongly associated with sex hormone–binding globulin (SHBG), some is more loosely bound to albumin, and a smaller fraction is unbound. As binding-protein levels vary, total and free measures can convey different information. Such distinctions matter in testosterone screening research.

The Endocrine Society’s guideline discusses the role of free testosterone assessment in specific interpretive circumstances and emphasizes accurate measurement methods. That is a statement about clinical evaluation standards, not a claim that every result requires every possible assay. [2]

In testosterone screening research, investigators should specify whether their endpoint is total, free or calculated free testosterone, how the measure was obtained, and whether reference intervals fit the assay. A study reporting one of these measures cannot automatically substitute its threshold for another.

6. Repetition helps distinguish persistent results from isolated values

The 2018 Endocrine Society guideline places repeat morning measurements in the context of compatible signs and symptoms and consistent biochemical evidence. Its 2026 statement reiterates the importance of at least two accurately measured early-morning tests in a clinician-led diagnostic framework. [2,3]

This is not simply a bureaucratic requirement. testosterone screening research identifies measurable variability from time of day, biological fluctuation and analytical uncertainty. A series of observations is conceptually better suited than one isolated observation to answering whether a low value persists.

No single count of samples resolves every possible uncertainty in research. Repetition improves information, but investigators still need clear eligibility criteria, standardized collection protocols and the appropriate clinical context. Repeated numbers do not replace an evaluation of what is being measured and why. This keeps testosterone screening research interpretable.

7. Prevalence from one threshold is not prevalence of a clinical disorder

A JAMA research letter published October 15, 2026 examined screening thresholds among active-duty U.S. male service members. Its question concerned the frequency of biochemical values below a stated boundary, not the prevalence of established hypogonadism. The published analysis involved a sample of 479 male soldiers; reports of its findings noted 124 below 300 ng/dL on a morning measurement. [5]

For testosterone screening research, that distinction is decisive. A count of people below one laboratory cutoff is not equivalent to the count who meet a clinician’s full diagnostic standard. Symptoms, persistence, laboratory quality and population characteristics can all alter interpretation. Nor does a sample drawn from one military population necessarily generalize to every civilian age group.

The news value of this research lies partly in exposing the difference between a screening percentage and a diagnosis. A dramatic headline can lose that distinction. Careful reporting preserves what the authors actually counted and does not use a single threshold result to imply that treatment is warranted. That precision matters for testosterone screening research.

testosterone screening research: study comparison

Source	Design or population	Verified finding	Interpretation boundary
Brambilla et al., JCEM 2009 [1]	Six sampling visits in 66 men aged 30–80	Among ages 30–40, 4 p.m. testosterone was 20–25% below 8 a.m. on average	Individual diurnal changes vary
Brambilla et al., Clinical Endocrinology 2007 [4]	Repeat hormone samples among 132 men	Biological and day-to-day variability contributed substantially to within-person differences	Reported ranges across hormones are not testosterone-specific constants
Endocrine Society guideline, 2018 [2]	Evidence-based professional guideline	Consistent symptoms and unequivocally, repeatedly low accurate measurements are central to diagnosis	Guidance is not a population prevalence estimate
Testosterone Trials, Snyder et al., NEJM 2016 [6]	Randomized trials in 790 men aged 65+ with symptoms and low screening values	Eligibility used a defined biochemical and clinical framework	Not a validation of diagnosis from one reading
JAMA military screening letter, October 2026 [5]	Cross-sectional screening study of 479 active-duty men	124 were reported below the 300 ng/dL threshold	One result below a cutoff does not count diagnosed cases

The entries answer different research questions. One demonstrates daily variation, another characterizes repeat-measurement uncertainty, a guideline synthesizes evidence, a randomized trial defines eligibility, and a new research letter estimates threshold frequency in a specific cohort. Treating all five as interchangeable evidence for one diagnostic percentage would be a category error.

testosterone screening research is strongest when the measurement context travels with the number. A percentage without a denominator, a cutoff without an assay, or a screening result without its collection time can be technically accurate yet practically misleading.

Morning versus afternoon measurement

Hormone concentration is influenced by biological rhythms. In many men, testosterone tends to be higher earlier in the day, although the magnitude of the pattern changes with aging. Brambilla and colleagues demonstrated this pattern during hours when laboratory visits commonly occur, making the finding relevant to the design of both clinical and observational research. [1]

For testosterone screening research, the important point is not simply that “morning is higher.” It is that variation can change categorical assignments when a fixed cut point is applied. A measurement near a boundary can be classified differently depending on when it was taken, even before considering between-day fluctuation.

The age gradient adds a further complication. The 2009 investigation reported a larger morning-to-afternoon difference among younger men than older participants. Therefore, studies that combine age groups without considering timing may introduce uneven measurement bias. Differences attributed to age could partly reflect collection schedules.

Clock time also cannot be viewed in isolation from sleep-wake timing. Shift work, unusual sleep schedules and other circadian influences complicate the notion that a given hour has identical biological meaning for every participant. Investigators need to state their collection protocol and describe departures from it rather than assume that all samples are comparable. testosterone screening research should report these details.

testosterone screening research becomes more informative when its authors explain whether specimens were collected under standardized conditions and whether statistical analyses adjusted for timing. Without that information, two cohorts may appear to have different hormone distributions for reasons unrelated to true underlying endocrine health.

Biological and assay variability

Repeated sampling introduces several sources of variation: real biological fluctuation within a participant, random analytical noise and systematic differences between methods. Separating them matters because each has different implications for study reliability and interpretation. The distinction is central to testosterone screening research.

Brambilla and colleagues’ 2007 study attempted this separation using paired specimens and repeated visits. Biological fluctuations were a substantial part of the total observed differences. The authors concluded that one specimen often does not adequately characterize an individual’s usual hormone state. [4]

In testosterone screening research, a repeat value that differs from the first need not mean the person’s endocrine system abruptly changed from healthy to unhealthy or the opposite. Both values may fall within an expected range of variation. Assessing persistence is a statistical and contextual problem, not merely a matter of choosing whichever number seems most striking.

Analytical variation can be particularly troublesome when values are near a lower reference boundary. If different tests use different calibration standards or suffer from bias, a sample may be labelled below range in one method and within range in another. The Endocrine Society’s 2026 statement explicitly identifies this as a contributor to misclassification. [3]

Method standardization seeks to improve agreement, but it does not imply that every hormone result is exact. testosterone screening research requires attention to assay validation, quality control, reference intervals and traceability. Those features can seem unexciting compared with a headline percentage, yet they are essential for credible comparisons across studies. Quality infrastructure underpins testosterone screening research.

Another analytical issue concerns free testosterone. Direct measurements and calculated estimates may have different assumptions and sources of error. The relationship between total testosterone, SHBG and free hormone also varies with individual physiology. A paper should make clear which quantity its cutoff represents, rather than leaving readers to infer that all testosterone measures are equivalent.

Population studies may use data generated over many years or at multiple laboratories. Batch effects, equipment changes and method updates can introduce patterns mistaken for genuine time trends. If testosterone screening research compares groups collected under different laboratory conditions, its methods should explicitly account for those differences.

Why repeat evidence changes interpretation

A single result gives one point on a changing biological curve. Multiple appropriately collected measurements provide information about that curve’s stability. They can help distinguish a persistently low pattern from an isolated low point caused by timing or ordinary fluctuation.

The guideline framework does not reduce clinical interpretation to arithmetic. The Endocrine Society emphasizes compatible symptoms and signs, as well as consistently low concentrations measured accurately. Its July 2026 position statement also cautions against blanket population-level screening of asymptomatic men because evidence does not support a general recommendation for it. [2,3]

testosterone screening research thus has two separate questions: how well does a laboratory method measure hormone concentration, and how well does the entire evaluation identify a meaningful condition? A technically precise test may be poorly informative when used in the wrong population or interpreted without context.

The distinction is familiar elsewhere in screening science. A positive or below-threshold laboratory result can prompt further evaluation, but a screening test and a confirmed diagnosis are not synonyms. False positives and false negatives depend on measurement accuracy, chosen cutoff and the prevalence of the underlying condition.

When testosterone screening research estimates rates below a cut point, readers should look for the exact denominator, age distribution, timing of samples, assay type and whether values were confirmed. Without this information, the resulting percentage cannot readily be generalized to another population or interpreted as a disease rate.

The 2009 study’s example of 17 men with low afternoon readings but normal repeated morning values makes this issue tangible. It illustrates classification instability even when the same individuals are observed in a controlled research design. [1]

Repeated measurements, of course, have their own limits. If an underlying illness, medication exposure or sleep pattern changes between observations, values can shift for meaningful reasons. A researcher should document relevant circumstances rather than reflexively label every difference random noise. This is part of rigorous testosterone screening research.

Lessons from TTrials and the 2026 military research letter

The Testosterone Trials, often shortened to TTrials, were a coordinated group of randomized studies involving older men with symptoms and repeatedly low testosterone measurements. The New England Journal of Medicine primary report by Snyder and colleagues described 790 men aged 65 or older with screening testosterone below a specified level and relevant symptoms. The trials evaluated predefined outcomes over a year. [6]

The TTrials do not answer whether an arbitrary screening value diagnoses deficiency in a young adult. Their eligibility process was deliberately selective and differed from a one-time population survey. This contrast is important within testosterone screening research because a randomized intervention trial can be rigorous while applying only to a narrowly defined participant group.

The TTrials also demonstrate why a biomarker is not the same thing as a clinical outcome. Hormone concentration helped define eligibility, but the studies examined effects on sexual function, physical function and vitality. These endpoints did not all show identical patterns. Laboratory evidence and patient-relevant outcomes must be evaluated distinctly.

The October 2026 JAMA research letter provides a contrasting modern example. It assessed screening thresholds in active-duty U.S. male service members, a population quite different from the TTrials cohort. Its single-reading threshold analysis attracted attention because a substantial proportion of the sample fell below a commonly discussed boundary. [5]

But testosterone screening research cannot equate that proportion with a count of confirmed deficiency cases. The research-letter design did not turn every below-threshold concentration into a clinical diagnosis. The article’s population, collection protocol and cutoff should be discussed before anyone treats its percentage as a statement about all men.

Using the two studies together is instructive. One illustrates an eligibility framework built around repeated biochemical and clinical evidence in older symptomatic men. The other illustrates how a cross-sectional threshold can flag many people in a younger, specific population. They are complementary examples of different questions, not contradictory answers to one question.

The Endocrine Society’s 2026 statement provides timely context by reaffirming that broadly screening asymptomatic populations is not supported by sufficient evidence. [3] This is a research and public-health distinction, not a blanket claim that individual concerns are unimportant.

Research design and unanswered questions

One priority is assay harmonization. Research datasets are more comparable when laboratories use validated, traceable methods and transparent quality standards. Without that foundation, apparent differences between cohorts may partly be differences between instruments.

A second priority in testosterone screening research is careful characterization of repeated measures. Investigators can report how often a threshold crossing persists, how large day-to-day variation is in particular age groups and how much of the variation comes from sampling conditions rather than assay imprecision.

Third, future studies could assess different sleep-wake patterns and collection schedules. The classic morning-afternoon literature is useful, but its participants and schedules cannot represent every modern work pattern. Well-described timing would help distinguish biological circadian variation from practical sampling differences.

Fourth, researchers should evaluate the relationship between biochemical values, symptoms and functional outcomes without assuming that a single symptom is specific to testosterone deficiency. Fatigue, altered mood and changes in physical performance have multiple possible determinants. Biomarker associations alone cannot isolate causal pathways.

Fifth, testosterone screening research would benefit from reporting uncertainty, not merely the fraction below one cut point. Confidence intervals, distributional plots and sensitivity to alternate validated thresholds can reveal how strongly a result depends on analytical choices.

Sixth, the effects of age, body composition and health status on hormone distributions deserve careful study. These factors often overlap, making causal interpretation difficult in cross-sectional surveys. Longitudinal observation and transparent adjustment strategies can improve understanding without promising perfect causal answers.

Seventh, trial eligibility rules should be reported separately from population screening rules. A threshold chosen to recruit a homogeneous research cohort is not automatically a threshold that identifies a clinical disorder in everyone. testosterone screening research is most credible when it avoids this common category error.

Finally, scientific communication should resist binary headlines that portray one number as definitive. The evidence does not demand ignoring measurements; it demands interpreting them within a reliable framework. Accurate collection, repeatability, validated methods and meaningful context allow laboratory science to become more informative.

The take-home message of testosterone screening research is encouraging for laboratory quality: the limitations of one reading are measurable, and there are established ways for researchers to improve precision and clarity. One value can contribute evidence, but it cannot carry the entire conclusion on its own.

Frequently asked questions

1. Can one testosterone result confirm deficiency?

No. A single concentration is one measurement under one set of conditions. The Endocrine Society’s evidence-based framework considers compatible signs and symptoms together with consistently low, accurately measured values. testosterone screening research documents both biological and analytical reasons that isolated results may mislead. [2,3]

2. Why can morning and afternoon testosterone readings differ?

Testosterone follows a daily rhythm in many men. In Brambilla and colleagues’ 2009 study, late-afternoon concentrations averaged 20–25% lower than early-morning values among men aged 30–40, with a smaller age-related effect in older participants. That is a group finding, not a fixed percentage for every person. [1]

3. What does a laboratory cutoff such as 300 ng/dL mean?

It is a reference boundary used in certain screening and clinical frameworks, not a stand-alone diagnosis. testosterone screening research shows that the classification may depend on timing, repeatability, assay methods and the population. The same number cannot be interpreted without its context. [1–3]

4. Do repeated tests remove every source of uncertainty?

No. Repetition provides evidence of stability and reduces reliance on one isolated value, but collection conditions, biological variability and method quality still matter. Studies of intraindividual variation show that readings can differ even when they come from the same participant. [4]

5. Did the 2026 military study show that one-quarter of soldiers had diagnosed hypogonadism?

No. The October 2026 JAMA letter examined the frequency of testosterone values below a screening threshold in a specific active-duty population. testosterone screening research distinguishes that biochemical count from a confirmed clinical diagnosis requiring additional evidence. [5]

References

1. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab. 2009;94(3):907–913. https://pubmed.ncbi.nlm.nih.gov/19088162/
2. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. https://doi.org/10.1210/jc.2018-00229
3. Endocrine Society. Statement on Testosterone Replacement Therapy. July 16, 2026. https://www.endocrine.org/news-and-advocacy/news-room/2026/statement-on-testosterone-replacement-therapy
4. Brambilla DJ, O’Donnell AB, Matsumoto AM, McKinlay JB. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clinical Endocrinology. 2007;67(6):853–862. https://pubmed.ncbi.nlm.nih.gov/18052942/
5. Berryman CE, et al. Testosterone Screening Thresholds in Active-Duty US Male Service Members. JAMA. October 15, 2026. doi:10.1001/jama.2026.19794. https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.19794
6. Snyder PJ, Bhasin S, Cunningham GR, et al.; Testosterone Trials Investigators. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374:611–624. https://pubmed.ncbi.nlm.nih.gov/26886521/

For laboratory research use only. Not for human consumption.